Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine for Seneca virus A (HB16 strain) as a new veterinary drug [1] Group 1: Company Developments - Keqian Bio has been granted a new veterinary drug registration certificate for its inactivated vaccine targeting Seneca virus A, which is significant for the company's product portfolio [1] - The approval aligns with the regulations set forth in the Veterinary Drug Administration Regulations and the Veterinary Drug Registration Measures [1] Group 2: Industry Context - Seneca virus disease, caused by Seneca virus A, primarily affects pigs and is characterized by lesions that can be confused with other diseases such as foot-and-mouth disease and vesicular stomatitis [1] - The disease has been reported in countries like Canada, Brazil, and the United States, indicating its prevalence and the potential market need for effective vaccines [1]

Core Viewpoint - The company, Keqian Bio (688526.SH), has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its inactivated vaccine against Seneca virus disease in pigs, marking a significant advancement in veterinary medicine [1] Group 1: Company Developments - Keqian Bio has been granted a new veterinary drug registration certificate for its inactivated vaccine (HB16 strain, suspension culture) [1] - The approval is in accordance with the Veterinary Drug Administration Regulations and the Veterinary Drug Registration Measures [1] Group 2: Industry Context - Seneca virus disease, caused by Seneca virus A (SVA), is a viral infectious disease primarily affecting pigs, characterized by lesions similar to foot-and-mouth disease and other diseases [1] - The disease is transmitted mainly through contact and has been reported in countries such as Canada, Brazil, and the United States [1]